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Abstract
Objective: To determine whether increased antithrombin loss is present in children with chylothorax after cardiac surgery. Methods: Plasma
and pleural effusion samples of children with chylous and non-chylous pleural effusion were assayed for antithrombin activity. Results: Ten
children with chylothorax and five children with non-chylous pleural effusion were investigated. There was statistically significant increase in
mean antithrombin activity in chylous samples (32.2  11.4%) compared to non-chylous samples (14.4  13.9%), and significant decrease in
plasma of children with chylothorax (44.6  15.4%) compared to children with non-chylous pleural effusion (69.9  22.4%). Seven of 10 children
with chylous and none of the children without chylous developed thrombosis (p < 0.007). Conclusions: Increased loss of antithrombin is present
in children with chylothorax, potentially predisposing these children to an increased risk of thrombosis. Repeated antithrombin substitution
should be considered in critically ill children with chylothorax.
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Antithrombin (AT) is the most important natural
inhibitor of the coagulation cascade. By inhibiting the
activity of most coagulation proteases including thrombin,
factor (F) Xa, FIXa, FXIa, and FXIIa, AT prevents uncon-
trolled coagulation and thrombus formation [1]. Inherited
or acquired deficiencies of AT lead to a significant increase
in the risk of thrombosis. While inherited deficiency of AT is
rare in the general population, acquired deficiency is
frequently observed in patients with liver disease, nephro-
tic syndrome, and after major surgery, particularly cardiac
surgery [2].
Chylothorax is a collection of a whitemilky drainage from
the lymphatic systemwithin the thoracic cavity. Chylothorax
commonly develops secondary to thrombosis and/or high
pressure in the superior vena cava, and an iatrogenic
laceration of the thoracic duct during intrathoracic proce-
dures [3,4]. Chylous is rich on fat and proteins of small
molecular size, and contains all blood components except
red cells and platelets [3]. This study aims to determine
whether increased AT loss is present in children with
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2.1. Patient population
A cohort of consecutive children diagnosed with chy-
lothorax after cardiac surgery at the University Children’s
Hospital of Zurich was included in this study. The initial
suspicion of chylothorax due to the presence of a milky white
pleural effusion was confirmed by laboratory examination of
the pleural effusion in accordance to previously published
diagnostic criteria, including (1) >1.1 mmol/L triglycerides
(with oral fat intake) and (2) a total cell count >1000 cells/
mL, with a lymphocyte fraction >80% [5]. Chylothorax was
treated according to our hospital guidelines. Initial con-
servative management includes drainage of the pleural
cavity and oral fat-free nutrition during 7 days, followed by 7
days of total parenteral nutrition with or without somatos-
tatin infusion if chylous effusion persists. In children showing
resolution of chylothorax, oral fat-free nutrition is continued
for a total of 6 weeks. In children showing chyle leak for more
than 4 weeks, a pleurodesis is performed. Age-matched
children with non-chylous pleural effusion treated at the
same institution served as controls. Clinical data collected of
all children included underlying disease, type of surgery, and
history of thrombosis. This study was approved by the
Research Ethics Boards of the University Children’s Hospital,
Zurich, Switzerland.
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Table 1
Baseline characteristics of children with chylous and non-chylous pleural
effusion
Characteristics Pleural effusion
Chylous (n = 10) Non-chylous (n = 5)
Sex (n)
Male 5 3
Female 5 2
Age (months)
Mean 13.9 27.2 *
Median 1.5 30*
Range 1—42 1—42
Weight (kg)
Mean 5.3 11.6 *
Median 3.9 11.4 *
Range 2.1—12.1 3.2—22.0
Pleural effusion (mL/day)
Mean 315.5 291*
* Not significant differences.2.2. Laboratory methods
Chylous samples were collected on day 2—4 postopera-
tively when chylothorax diagnosis was confirmed. At the
time of sample collection, all children with chylothorax
were still on normal nutrition. Blood and pleural effusion
samples were collected at the same time into 0.106 M
buffered tri-sodium citrate. An assumption in both groups
was that pleural effusion was not blood stained to prevent a
contamination with AT. Measurements of AT activity in both
plasma and pleural effusion were performed by a photo-
metric assay (Coacute Antithrombin R, Chromogenix
Instrumentation Laboratory SpA, Milan, Italy) following
guidelines of the manufacturer. Briefly, samples were
diluted with a buffer containing an excess of heparin.
Aliquots of these sample dilutions were added to a cuvette
containing a lyophilized mixture of FXa and a FXa-specific
chromogenic substrate. After 5 min incubation, a stopper
solution was added and absorbance of samples was read at
405 nm. Concentration of AT in percent of normal levels
were derived from the appropriate standard curve given in
the batch-specific insert.
2.3. Statistical analysis
Data of AT activity are expressed as means  standard
deviation (SD) as appropriate. Statistically significant
differences between children with chylous and controls as
regarding age, weight, amount of pleural effusion, and AT
values in plasma and pleural effusion were tested by the
Mann—Whitney test. Categorical variables were tested by
Fisher’s exact test. A p-value < 0.05 was considered
significant. Analysis was performed by means of GraphPad
InStat for Windows (GraphPad Software, San Diego, CA, USA;
version 3.05).Fig. 1. Antithrombin activity in pleural effusion samples of children with
chylothorax and children with non-chylous pleural effusion. Data are shown
as mean (bar)  standard deviation (vertical line).3. Results
3.1. Patient population
A total of 10 children (mean age, 14  23.5 months) with
chylothorax and 5 children (mean age, 27  15.7 months)
with non-chylous pleural effusionwere included in the study.
Baseline characteristics of children with chylous and non-
chylous pleural effusion are depicted in Table 1. Chylothorax
had developed following cardiopulmonary bypass for con-
genital heart disease in all 10 patients. Non-chylous pleural
effusion consisting of exudate had developed following
cardiac surgery (Norwood I; repair of transposition of the
great vessels) in two children, and as a complication of
pneumonia in the other three children. Seven (70%) of the 10
children with chylothorax developed thrombosis during the
course of the disease. Thrombosis was located in the aortic-
pulmonary shunt (n = 1), the right iliac artery (n = 2), the left
iliac artery (n = 1), the right subclavian vein (n = 2), and the
cava superior vein (n = 1). In one child, thrombus extended
in the superior vena cava, the jugular and subclavian vein,
and in the cerebral sinus veins. None of the five patients with
non-chylous pleural effusion developed thrombotic compli-
cations ( p = 0.02).3.2. Antithrombin activity in pleural effusion and plasma
Mean AT activity was significantly increased in chylous
samples (32.2  11.4%) compared to non-chylous samples
(14.4  13.9%) (Fig. 1), and significantly decreased in plasma
of children with chylothorax (44.6  15.4%) compared to
children with non-chylous pleural effusion (69.9  22.4%)
(Fig. 2). Mean antithrombin activity in children with
chylothorax was also clearly decreased as compared to the
published mean values of antithrombin in both healthy
children aged 1—5 years and infants and young children on
the second postoperative day following cardiac surgery
(Fig. 2) [6—8].
In children with chylothorax, mean AT activity in chylous
and plasma samples were not statistically different. By
contrast, in children with non-chylous pleural effusion, mean
AT activity in plasma samples was significantly increased as
compared to the AT measured in non-chylous pleural effusion
samples ( p = 0.007).
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Fig. 2. Antithrombin activity in serum samples of children with chylothorax
and children with non-chylous pleural effusion. Data are shown as mean
(bar)  standard deviation (vertical line). The bar A shows the mean normal
value of antithrombin in healthy children aged 1—5 years [6,7]. The bar B shows
the published mean value  standard deviation (vertical line) of antithrombin
in infants and young children on the second postoperative day following
cardiac surgery [8].4. Discussion
Chylothorax is a severe complication of cardiothoracic
procedures causing the loss of large amounts of fluids and
proteins, and consequently leading to an increased morbidity
possibly compromising the postoperative course [2—4]. The
aim of this study was to compare ATactivity in children with
chylothorax and non-chylous pleural effusion. Results of this
study indicate that increased loss of AT is present in children
with chylothorax, possibly increasing the thrombotic risk in
these patients.
The chylous transported by the thoracic duct contains a
combination of lymphatic and gut-derived substances
including lymphocytes, immunoglobulins, electrolytes,
enzymes, and fat. Iatrogenic lesions of the thoracic duct
during cardiothoracic procedures cause the loss of large
amount of chylous in the pleural cavity, and may lead to
immunosuppression, electrolyte dysbalance, and malnutri-
tion [3]. While the loss of large amount of coagulation
proteins including fibrinogen and prothrombin with an
increased risk of hemorrhagic complications has been
described in patients with chylothorax, data on important
inhibitors of coagulation possibly lost in chylous are not
available. Despite the small number of patients, results of
this study show that significantly increased loss of AT is
present in children with chylothorax leading to a significantly
decreased AT activity in plasma of these patients. These
findings also suggest that decreased plasma AT activity may
limit optimal anticoagulation and increase the risk of
thrombosis in these children.
While advances in cardiac surgery techniques have
significantly improved the survival rate of children with
congenital heart disease, children undergoing cardiac
surgery have become one of the major pediatric population
developing thrombosis as secondary complication [9].
Several possible risk factors such as age, type of surgery,
central venous lines, and low cardiac output have beenreported in children with thrombosis following cardiac
surgery [10]. As well, previous studies have demonstrated
a global decrease of all components of the coagulation and
fibrinolytic system in children undergoing cardiopulmonary
bypass [8,11,12]. However, the role of coagulation disorders
due to chylothorax in the development of thrombosis in these
children has not been assessed so far. Our findings of
increased AT loss in children with chylothorax together with
the increased rate of thrombosis in these children suggest
that chylothorax possibly represents a further risk factor for
thrombosis in children undergoing cardiopulmonary bypass.
Although in our seven patients developing thrombosis, a
direct correlation between chylothorax and thrombotic
event can be neither excluded nor confirmed, our data
suggest that thrombosis should be considered not only a
possible etiology but also a consequence of chylothorax.
These findings also suggest that repeated antithrombin
substitution should be considered in critically ill children
with chylothorax.
Results of this study should be interpreted in the light of
potential study limitations. Beside the small number of
patients, the heterogeneous nature of children with non-
chylous pleural effusion may have led to a misinterpretation
of statistical differences in AT values between children with
chylous and non-chylous pleural effusion. However, mean
antithrombin activity in children with chylothorax was also
clearly decreased as compared to the published mean values
of antithrombin in both healthy children aged 1—5 years and
infants and young children following cardiac surgery.
Although of preliminary nature, results on antithrombin
activity in our children with chylothorax describe a real
problem causing significant management dilemmas in
pediatric intensive care units, and provide the basis for
further studies aiming to investigate the relation between
chylothorax and thrombosis.
In summary, although both the small number of patients
and the heterogeneous nature of the control group are
clearly study limitations, results of this study show that an
increased loss of AT is present in children with chylothorax,
potentially predisposing these children to an increased risk
of thrombosis. Repeated antithrombin substitution should
be considered in these children to prevent thrombotic
complications and optimize heparin therapy in those
children requiring anticoagulation. Large studies are
required to further investigate haemostasis in children
with chylothorax, and the role of increased loss of all
coagulation inhibitors in the development of thrombosis in
these children.
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